Bombay Oxygen Investment Limited, previously known as Bombay Oxygen Corporation, was established in October 1960 with the aim of manufacturing and marketing industrial gases. The name of the company was officially changed to Bombay Oxygen Investment Limited on October 3, 2018. It operates as a Non-Banking Financial Company (NBFC) registered with the Reserve Bank of India and maintains manufacturing facilities in Nagpur, Tarapur, Pune, Nira, Khopoli, Kalwe, and Mulund, all situated in Maharashtra.
Initially, the company's core business centered around the production and supply of industrial gases, which ceased on August 1, 2019. Presently, its main source of revenue stems from substantial financial investments in shares, mutual funds, and other financial securities.
Bombay Oxygen Investment Limited has a collaborative partnership with General Electrodes and Equipments, Germany, and previously engaged Messer AGS Gmbh for engineering services under an agreement. The company installed a manufacturing capacity of 2.37 lac cu mtr for oxygen in March 1995 and produces various industrial gases including oxygen, nitrogen, argon, compressed air, acetylene, and medicinal oxygen. Its subsidiaries, Savita Pharmaceuticals and Raptakos Brett & Company, are involved in pharmaceutical manufacturing and distribution.
The company developed an indigenous cryogenic liquid oxygen pump for high-pressure gas-filling purposes. In 1996, it divested its shares in Raptakos Brett & Co., leading to the cessation of Raptakos Brett & Co. and its subsidiaries, Raptakos Brett Test Laboratories, and Sattva Pharmaceuticals, as subsidiaries of the company.
In terms of plant commissioning, the Tonnage Oxygen Plant at Kalwe was inaugurated in June 2003, and the 40 TPD Oxygen Liquifier Plant at Kalwe commenced operations in March 2005.
Initially, the company's core business centered around the production and supply of industrial gases, which ceased on August 1, 2019. Presently, its main source of revenue stems from substantial financial investments in shares, mutual funds, and other financial securities.
Bombay Oxygen Investment Limited has a collaborative partnership with General Electrodes and Equipments, Germany, and previously engaged Messer AGS Gmbh for engineering services under an agreement. The company installed a manufacturing capacity of 2.37 lac cu mtr for oxygen in March 1995 and produces various industrial gases including oxygen, nitrogen, argon, compressed air, acetylene, and medicinal oxygen. Its subsidiaries, Savita Pharmaceuticals and Raptakos Brett & Company, are involved in pharmaceutical manufacturing and distribution.
The company developed an indigenous cryogenic liquid oxygen pump for high-pressure gas-filling purposes. In 1996, it divested its shares in Raptakos Brett & Co., leading to the cessation of Raptakos Brett & Co. and its subsidiaries, Raptakos Brett Test Laboratories, and Sattva Pharmaceuticals, as subsidiaries of the company.
In terms of plant commissioning, the Tonnage Oxygen Plant at Kalwe was inaugurated in June 2003, and the 40 TPD Oxygen Liquifier Plant at Kalwe commenced operations in March 2005.
